Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 11/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8052859 | 0.83 | GRIN1 (0.39) | GRIN1GRIN2BCES2S1PR5 | |
| SCHEMBL8066849 | 0.82 | CES2 (0.38) | GRIN1GRIN2BCES2S1PR5 | |
| SCHEMBL12678485 | 0.80 | GRIN1 (0.38) | GRIN1GRIN2BCES2F2R | |
| SCHEMBL8815186 | 0.80 | GRIN2B (0.40) | GRIN1GRIN2BCES2 | |
| SCHEMBL8813978 | 0.78 | GRIN1 (0.37) | GRIN1GRIN2BCES2 | |
| SCHEMBL3027726 | 0.76 | GRIN1 (0.37) | GRIN1GRIN2BMAPK14 | |
| SCHEMBL8815542 | 0.71 | SLC6A7 (0.36) | GRIN1GRIN2BCES2 | |
| SCHEMBL8066822 | 0.70 | PGR (0.35) | GRIN1GRIN2BCES2HTR7F2R | |
| SCHEMBL12678475 | 0.69 | SMN1; SMN2 (0.41) | GRIN1GRIN2BCES2 | |
| SCHEMBL12678479 | 0.68 | GRIN1 (0.36) | GRIN1GRIN2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | GRIN1 134/4885GRIN2B 109/4885CES2 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.